This division is specialized in Stem Cell Research & Therapy, Regenerative Medicine, Bio-artificial organ scaffolds development, nanobiotechnology, Nanoformulation of cancer Drugs, Molecular genetics, and Molecular virology, Stem cell and Cord blood banking while simultaneously imparting advanced learning aimed at expanding and adding to the body of scientific knowledge.
Through a transparent structure, the Research Unit will focus on R&D in stem cells and therapy through the Origin Hospital. The Stem Cell therapy focuses on the body organs of Liver, Pancreas, Neural, cardiac, Vascular, Renal and Ortho. The focus is mainly on stem cell therapy for end stage diseases and development of novel strategies for disease prognosis and treatment.
This division has successfully treated more than 300 patients in gastroenterology and Neurosciences through stem cell therapy. The platform has state-of-the-art research labs with well-trained team and have more than 250 international publications and two patents to their credit.
This division focuses on large unmet medical and market needs with reduced risk and high reward molecules. The division is currently working on 5 therapeutic areas of Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease and has been granted 11 international patents. Most of the above molecules have the ability to qualify for 505(b) 2 approval process as per USFDA. Adopting the concept of prodrug and selection of orphan drugs enables Less time frame, cost, and regulatory hurdles in comparison with New Chemical Entities.
The new drug discovery and development process of Dr Habeebullah Life Sciences is based on IP protected, low risk innovative platform. This, coupled with the strategy of selecting orphan drug category for the product portfolio gives the Company an added advantage to commercialize its NME’s at a proof-of-concept stage.
This division established a unique model of developing new panel of miRNAs as a novel Bio Marker and file the patent as an innovative Kit.
The medical devices division is effortlessly working towards efficient management of chronic diseases through development of extra-corporeal liver support device for the management of acute liver failure, Bioengineering implantable humanized nerve conduits for spinal cord injury, development of implantable nanochips carrying insulin producing cells for the management of uncontrolled diabetes mellitus, development of extra-corporeal device for the removal of circulating tumor cells(CTCs) from cancer patients and sepsis removal using nanotechnology-based extracorporeal device.